Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Editas Medicine Inc
EDIT
Healthcare
Biotechnology
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia...
. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:EDIT)
New Post
View:
Posts & Comments
Threaded Posts
(102)
•••
Napcoo
X
Comment by
Napcoo
on May 21, 2024 10:02pm
RE:Ruby study expected to be completed Aug 2025
https://www.globenewswire.com/news-release/2020/12/05/2140152/0/en/CRISPR-Therapeutics-and-Vertex-Present-New-Data-for-Investigational-CRISPR-Cas9-Gene-Editing-Therapy-CTX001-at-American-Society-of
...more
(102)
•••
Napcoo
X
Post by
Napcoo
on May 16, 2024 11:11pm
Ruby study expected to be completed Aug 2025
https://www.clinicaltrials.gov/study/NCT04853576
How Smart Investors Are Positioning for the Next Innovation Cycle
posted May 13, 2026 9:00am by
Stockhouse Publishing Ltd.
-
|
Gain a sharper edge with data-backed insights into disruptive technologies, innovation trends, and evolving investor opportunities. Explore Episode 1 and discover what could define the next generation of market leaders. ...Learn More
(52)
•••
0checker
X
Comment by
0checker
on Aug 19, 2021 8:20pm
RE:Genome Therapy New Biotech Darling?
https://www.innovationnewsnetwork.com/crispr-technology-achieves-dna-repair-in-space-for-the-first-time/14184/
(0)
•••
chiefmissile
X
Comment by
chiefmissile
on Dec 27, 2020 10:59am
RE:Genome Therapy New Biotech Darling?
Hi there, in the recent Jeff Brown pitch for his "exponential tech investor" he talks about a small cap biotech company, now he gave away a couple of clues. The company is owned by
...more
(0)
•••
bcwildthing
X
Post by
bcwildthing
on Nov 03, 2020 8:48am
Genome Therapy New Biotech Darling?
Just finished getting pitched Jeff Brown's newsletter for a small cap gene therapy company. I'm not sure which is his pick, but EDIT seems close to trial results showing up. Anyone have any
...more
(24)
•••
Kanoli
X
Post by
Kanoli
on Jul 06, 2020 4:06pm
1st Human Clinical Trial
When is this news going to be released? They said results would be a month and we are well past that. Any insight or idea when?
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
MindBio Develops Fatigue Prediction Model using Speech Analytics and AI
Podcasts